Lupin launches hydrocodone bitartrate generic
BALTIMORE — Lupin launched hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg in the United States.
Lupin’s hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg are the AA rated generic equivalent of Mikart’s hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg. It is indicated for the relief of moderate to moderately severe pain.
Hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg had combined sales of $79.6 million.
No comments found
Mayne Pharma acquires rights to fentanyl TDS
ADELAIDE, South Australia — Mayne Pharma acquired the rights to the fentanyl transdermal delivery system, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr from Par Pharmaceutical, which allows the company to now market the product in the United States.
This product was developed by Corium, a specialty pharmaceutical company focused on the development and manufacture of transdermal and transmucosal delivery systems. Fentanyl TDS is a generic equivalent to Duragesic, indicated for the management of pain in opioid-tolerant patients, severe enough to require daily treatment.
Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium. “We are very pleased to have partnered with Corium on another complex, difficult-to-develop and manufacture product,” said Mayne Pharma’s CEO Scott Richards. “The U.S. transdermal patch market is valued at more than $3.3 billion and is a well-regarded advanced drug delivery system that can better control drug release and can also lead to improved patient convenience and compliance.”
According to IMS Health, the annual market sales for the fentanyl patch were approximately $560 million for the 12 months ending Dec. 31.
“Mayne Pharma’s first marketed patch was Clonidine, indicated for the treatment of hypertension and is one of Mayne Pharma’s top five generic products by sales,” said Richards. “Our alliance with Corium now includes two marketed and one pipeline product that is filed with the U.S. Food and Drug Administration and reinforces one of the key strategic benefits of the Teva Portfolio acquisition to access a pipeline of new product opportunities through leveraging relationships with active pharmaceutical ingredient suppliers and contract development and manufacturing companies.”
No comments found
SoFi takes a look at best-value pharmacy schools
The San Francisco high salary is all well and good, but don't forget to factor in the fact that this is THE MOST EXPENSIVE city in which to live. You cannot compare $ to $ from city to city. Apples and oranges my friend.